Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Palatin announces the initiation of a Phase 2 clinical study of Bremelanotide co-administered with a PDE5i for the treatment of erectile dysfunction (ED)
These medications are quite expensive if theyre not covered by insurance, and a lot of people cant afford that. Foundayo and Zepbound now covered for millions of Americans
BMC Musculoskeletal Disord
Combined cost may be prohibitive for some patients
Given Lilly's aggressive patent protection strategy (as seen with tirzepatide), affordable retatrutide options through compounding may be limited initially
Innovators cannot afford to be bystanders as stakeholder perceptions of AOMs are being formed, especially with the AOM market at the cusp of becoming more crowded and competitive
US$ 29.09
US$ 20.73
US$ 23.49
US$ 25.98
